Squamoid Eccrine Ductal Carcinoma: Treatment and Outcomes

Am J Dermatopathol. 2022 Apr 1;44(4):249-253. doi: 10.1097/DAD.0000000000002072.

Abstract

Background: Squamoid eccrine ductal carcinoma (SEDC) represents a subtype of eccrine carcinomas that are diagnostically challenging for both clinicians and dermatopathologists.

Objective: To provide an updated review of SEDC and examine patient outcomes with different treatment modalities.

Methods: A review of Ovid MEDLINE was performed to review the English language medical literature of SEDC.

Results: A comprehensive review of clinical presentation, histologic findings, rates of lymphovascular and metastatic disease, treatment modalities and recurrence rates are reviewed.

Limitations: There is a limitation on available data because of the rare incidence.

Conclusions: SEDC is a rare adnexal neoplasm with a relatively high rate of local recurrence, lymphovascular invasion, perineural invasion, and metastases. Clinicians should be aware of this entity as close follow-up is essential to detect recurrence and metastatic disease. Mohs micrographic surgery seems to result in superior patient outcomes.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Carcinoma, Ductal / diagnosis*
  • Carcinoma, Ductal / pathology
  • Carcinoma, Ductal / surgery
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / surgery
  • Cheek
  • Diagnosis, Differential
  • Eccrine Glands*
  • Humans
  • Male
  • Mohs Surgery
  • Sweat Gland Neoplasms / diagnosis*
  • Sweat Gland Neoplasms / pathology
  • Sweat Gland Neoplasms / surgery